Results 121 to 130 of about 14,948 (182)

Prevention of 6-hydroxydopamine neurotoxicity

European Journal of Pharmacology, 1975
1-Phenyl-3-(2-thiazolyl)-2-thiourea (PTTU) prevented the neurotoxic actions of 6-hydroxydopamine on adrenergic nerves in the mouse atrium and iris. This is the first reported 6-hydroxydopamine antagonist that does not act by blocking uptake of catecholamines into nerve terminals. PTTU also prevented the diabetogenic action of alloxan.
Catherine Mytilineou
exaly   +3 more sources

6-Hydroxydopamine, a new oxidation mechanism

European Journal of Pharmacology, 1972
Abstract Electrochemical and chemical studies, supported by EPR, NMR and UV evidence, show that 6-hydroxydopamine does not oxidize in vitro at physiological pH to the cyclized indoline (aminochrome) as previously believed. The implications of these results to the chemical sympathectomy actions of 6-hydroxydopamine are discussed.
R N Adams, R N Adams
exaly   +3 more sources

Behavioral pharmacology of 6-hydroxydopamine

Life Sciences, 1973
Publisher Summary This chapter reviews the behavioral pharmacology of 6-hydroxydopamine. The ability of 6-hydroxydopamine (6-HDA) to produce a specific degeneration of central catecholamine-containing neurons offers a unique opportunity to study the consequences of loss of these neurons on the performance of a conditioned response. The 6-HDA treatment
R.I. Schoenfeld, M.J. Zigmond
openaire   +1 more source

Central effects of 6-hydroxydopamine

Physiology & Behavior, 1971
Abstract The central effects of 6-hydroxydopamine (6-OHDA) injected intracerebrally in mice and intracisternally in rats have been studied. Mice treated with 100 μg of the drug were sedated and lethargic, with reduced spontaneous activity, for periods of up to 8 days after injection. For a similar period, the response to amphetamine consisted only of
A S, De Carolis   +3 more
openaire   +2 more sources

6-Hydroxydopamine and Aggression in Cats

Pharmacology Biochemistry and Behavior, 1981
The effect of 6-hydroxydopamine (6-OHDA) injected into the cerebral ventricles on behaviour of singly- and group-housed cats was investigated. 6-OHDA in doses of 0.5, 1 and 2 mg was administered every morning for 5 to 8 days. In small doses 6-OHDA in singly- and group-housed cats evoked motor phenomena such as tremor, ataxia, rigidity, weakness and ...
D B, Beleslin   +2 more
openaire   +2 more sources

Modification of different morphine actions by 6-hydroxydopamine and 6-hydroxydopamine plus desmethylimipramine

Psychopharmacology, 1980
After intracisternal 6-hydroxydopamine (6-OHDA) in mice, brain noradrenaline (NA) and dopamine (DA) are diminished, although the reduction of NA is more pronounced. Intracisternal injection of 6-OHDA in desmethylimipramine (DMI)-pretreated animals strengthens the depletion of DA while NA is partly protected.
V, Fuchs, H, Coper
openaire   +2 more sources

The 6-Hydroxydopamine model of parkinson’s disease

Neurotoxicity Research, 2007
The neurotoxin 6-hydroxydopamine (6-OHDA) continues to constitute a valuable topical tool used chiefly in modeling Parkinson's disease in the rat. The classical method of intracerebral infusion of 6-OHDA involving a massive destruction of nigrostriatal dopaminergic neurons, is largely used to investigate motor and biochemical dysfunctions in Parkinson ...
SIMOLA, NICOLA   +2 more
openaire   +4 more sources

Effects of 6-Hydroxydopamine on Sleep in the Rat

Nature, 1971
THERE is evidence that biogenic amines are involved in the mechanisms of sleep1,2. Although the exact relationship is not clear, recent results suggest that decreases in the concen-tration of catecholamines (noradrenaline or dopamine) in the brain cause increased desynchronized sleep (D) (sleep with rapid desynchronized cortical activity, also known as
E, Hartmann   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy